Oncology

The assistant professor of microbiology at Penn Medicine discussed further research to be done with EGR2 and type 1 interferon.

Iovance Biotherapeutics also reported that it received positive regulatory feedback from the FDA regarding the IOV-LUN-202 clinical trial for LN-145.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The phase 1/2a clinical trial will take place at the University of Texas MD Anderson Cancer Center, aiming to enroll more than 100 patients.

The new fast track designation is for Reqorsa in combination with Tecentriq for an extensive-stage small cell lung cancer indication.

Marwan G. Fakih, MD, discusses how the BASECAMP-1 and EVEREST-1 trials will work in concert, diving into the unique mechanism of action of A2B530.

Review top news and interview highlights from the week ending July 14, 2023.

Among 16 patients who were treated with Caribou Biosciences’ CB-010, the ORR was 94% and the CR rate was 69%.

The guidance outlines recommendations for managing and reporting CGT manufacturing changes and PMR noncompliance.

The chief scientific officer at Candel Therapeutics discussed progress in investigations with CAN-3110 and CAN-2409.

The proof-of-concept trial was in healthy volunteers, and additional studies are being planned in patients with blood cancers undergoing hematopoietic stem cell transplants.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Hemogenyx is currently remanufacturing the therapy without the identified splicing issue.

The senior research fellow at Fred Hutch Cancer Center discussed research trends at the 2023 ASGCT meeting.

ACE1831 is Acepodia’s first γδ T-cell therapy to enter clinical trials.

Review top news and interview highlights from the week ending July 7, 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Mary “Nora” Disis, MD, director of University of Washington Medicine’s Cancer Vaccine institute, discussed past and current clinical trials for investigational CAR-T therapies in ovarian cancer.

The cofounder and chief executive officer of NKILT Therapeutics discussed unique advantages of the CIR platform.

Mary “Nora” Disis, MD, director of University of Washington Medicine’s Cancer Vaccine institute, discussed research she coauthored that was presented at ASCO’s 2023 conference.

The chief medical officer of Trisalus Life Sciences discussed studies evaluating the company’s PEDD system.

Review top news and interview highlights from the week ending June 30, 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The vice president of business development and alliances at Prescient Therapeutics discussed advantages of the OmniCAR, SpyTag, and SpyCatcher technologies.

Updated data are from a total of 36 patients treated in a phase 1/2 study as of June 2023.